Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ebalzotan SCHEMBL6370473 | 1.00 | DRD2 (0.77) | DRD2 | |
| Hydrochloric Acid SCHEMBL8823814 | 0.90 | DRD2 (0.77) | DRD2 | |
| Hydrochloric Acid SCHEMBL8823793 | 0.89 | DRD2 (0.76) | DRD2 | |
| SCHEMBL9568770 | 0.89 | DRD2 (0.76) | DRD2 | |
| SCHEMBL8823678 | 0.88 | DRD2 (0.78) | DRD2 | |
| SCHEMBL8823628 | 0.88 | DRD2 (0.78) | DRD2 | |
| SCHEMBL8823789 | 0.87 | DRD2 (0.76) | DRD2 | |
| SCHEMBL8823704 | 0.87 | DRD2 (0.58) | DRD2 | |
| SCHEMBL8823697 | 0.87 | DRD2 (0.58) | DRD2 | |
| SCHEMBL8823639 | 0.86 | DRD2 (0.82) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2020210643-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2020-10-15 | — | — | WO | claimed |
| EP-2086544-B1 | USE OF TESTOSTERONE AND A 5-HT1A AGONIST IN THE TREATMENT OF SEXUAL DYSFUNCTION | EB IP LYBRIDOS B V (NL) | 2015-12-23 | — | — | EP | claimed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| EP-2937086-A1 | USE OF TESTOSTERONE AND A 5-HT1A AGONIST IN THE TREATMENT OF SEXUAL DYSFUNCTION | EB IP Lybridos B.V. (NL) | 2015-10-28 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-103381270-A | Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction | EMOTIONAL BRAIN BV | 2013-11-06 | — | — | CN | claimed |
| EP-0969842-A1 | PHARMACEUTICAL COMPOSITION | R.P. Scherer Limited (GB) | 2000-01-12 | — | — | EP | claimed |
| WO-1998042344-A1 | PHARMACEUTICAL COMPOSITION | R. P. SCHERER LIMITED (GB) | 1998-10-01 | — | — | WO | claimed |
| US-5656658-A | Method for the treatment of anxiety | ASTRA AKTIEBOLAG (SE) | 1997-08-12 | — | — | US | claimed |
| US-5641807-A | Method for the treatment of depression | ASTRA AKTIEBOLAG (SE) | 1997-06-24 | — | — | US | claimed |
| US-5639784-A | ADMINISTERING 3-AMINO-5-CARBAMOYL-CHROMENES AND DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1997-06-17 | — | — | US | claimed |
| EP-0607274-B1 | 3-(N-ISOPROPYL-N-n-PROPYLAMINO)-5-(N-ISOPROPYL)CARBAMOYLCHROMAN | ASTRA AB (SE) | 1996-06-26 | — | — | EP | claimed |
| US-5420151-A | Chroman derivatives | AKTIEBOLAGET ASTRA (SE) | 1995-05-30 | — | — | US | claimed |
| EP-0607274-A1 | 3-(N-ISOPROPYL-N-n-PROPYLAMINO)-5-(N-ISOPROPYL)CARBAMOYLCHROMAN. | ASTRA AB (SE) | 1994-07-27 | — | — | EP | claimed |
| EP-0538222-A1 | 3-(N-Isopropyl-N-n-propylamino)-5-(N-isopropyl)carbamoylchroman as a selective 5-hydroxytryptamine receptor stimulant | Astra Aktiebolag (SE) | 1993-04-21 | — | — | EP | claimed |
| WO-1993007135-A1 | 3-(N-ISOPROPYL-N-N-PROPYLAMINO)-5-(N-ISOPROPYL)CARBAMOYLCHROMAN | AKTIEBOLAGET ASTRA (SE) | 1993-04-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | DRD2 345/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | DRD2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.